Welcome, Guest. Please login or register.
July 18, 2024, 03:54:26 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 203
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 55
Total: 55


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Cyramza Improves Survival for People With Liver Cancer  (Read 7328 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Cyramza Improves Survival for People With Liver Cancer
« on: May 04, 2018, 10:11:26 am »
Cyramza (ramucirumab), which slows tumor growth by blocking blood vessel formation, increased overall survival and progression-free survival in liver cancer patients with a specific biomarker, according to Phase III study results announced this week by Eli Lilly and Company.

The findings come from the REACH-2 trial, which tested Cyramza as a second-line treatment for people with hepatocellular carcinoma (HCC) who had high levels of alpha-fetoprotein (AFP), a biomarker associated with poor prognosis. The new results have not yet been presented at a scientific conference or published in a medical journal.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.